IL259818B - Isoindole compounds - Google Patents
Isoindole compoundsInfo
- Publication number
- IL259818B IL259818B IL259818A IL25981818A IL259818B IL 259818 B IL259818 B IL 259818B IL 259818 A IL259818 A IL 259818A IL 25981818 A IL25981818 A IL 25981818A IL 259818 B IL259818 B IL 259818B
- Authority
- IL
- Israel
- Prior art keywords
- isoindole compounds
- isoindole
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562267391P | 2015-12-15 | 2015-12-15 | |
PCT/EP2016/080885 WO2017102784A1 (en) | 2015-12-15 | 2016-12-14 | Isoindole compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
IL259818A IL259818A (en) | 2018-07-31 |
IL259818B true IL259818B (en) | 2021-05-31 |
Family
ID=57708552
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL259818A IL259818B (en) | 2015-12-15 | 2018-06-05 | Isoindole compounds |
Country Status (27)
Country | Link |
---|---|
US (4) | US10011566B2 (en) |
EP (1) | EP3390396B1 (en) |
JP (1) | JP6448867B2 (en) |
KR (1) | KR101947976B1 (en) |
CN (1) | CN109071516B (en) |
AR (1) | AR107054A1 (en) |
AU (1) | AU2016374294B2 (en) |
BR (1) | BR112018011851A2 (en) |
CA (1) | CA3007893A1 (en) |
CL (1) | CL2018001573A1 (en) |
CO (1) | CO2018005983A2 (en) |
CR (1) | CR20180328A (en) |
DO (1) | DOP2018000148A (en) |
EA (1) | EA034514B1 (en) |
ES (1) | ES2927631T3 (en) |
IL (1) | IL259818B (en) |
MX (1) | MX2018007296A (en) |
MY (1) | MY196276A (en) |
NI (1) | NI201800071A (en) |
PE (1) | PE20181319A1 (en) |
PH (1) | PH12018501237A1 (en) |
SG (1) | SG11201804587QA (en) |
SV (1) | SV2018005713A (en) |
TN (1) | TN2018000188A1 (en) |
TW (1) | TWI728017B (en) |
WO (1) | WO2017102784A1 (en) |
ZA (1) | ZA201804618B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109071516B (en) | 2015-12-15 | 2021-08-31 | 阿斯利康(瑞典)有限公司 | Novel compounds |
US11034654B2 (en) | 2017-06-14 | 2021-06-15 | Astrazeneca Ab | 2,3-dihydroisoindole-1-carboxamides useful as ROR-gamma modulators |
WO2020035557A1 (en) | 2018-08-17 | 2020-02-20 | Leo Pharma A/S | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |
WO2020035556A1 (en) | 2018-08-17 | 2020-02-20 | Leo Pharma A/S | Novel heteroaromatic modulators of the retinoid-related orphan receptor gamma |
AU2021269613A1 (en) * | 2020-05-15 | 2023-02-02 | Shanghai Litedd Co., Ltd. | Aniline compound used as RORγ regulator |
TW202146389A (en) * | 2020-05-15 | 2021-12-16 | 大陸商上海輝启生物醫藥科技有限公司 | Biaryl compound capable of serving as ror[gamma] modulator |
KR102422891B1 (en) | 2022-01-26 | 2022-07-20 | (주)셀시스템 | Integrated solar hot water and battery charging device with AI-based priority control function and charging method using the same |
WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9414139D0 (en) | 1994-07-13 | 1994-08-31 | Smithkline Beecham Plc | Novel compounds |
WO1997027852A1 (en) | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
TR200002445T2 (en) | 1998-02-25 | 2000-12-21 | Genetics Institute, Inc. | Phospholipase inhibitors. |
US6316503B1 (en) * | 1999-03-15 | 2001-11-13 | Tularik Inc. | LXR modulators |
EP1212065A4 (en) | 1999-07-08 | 2004-02-11 | Tularik Inc | Compositions and methods for raising hdl cholesterol levels |
ES2252230T3 (en) | 2000-05-11 | 2006-05-16 | Bristol-Myers Squibb Company | USEFUL TETRAHYDROISOQUINOLINE ANALOGS AS SECRETORS OF GROWTH HORMONE. |
WO2002020463A2 (en) | 2000-09-05 | 2002-03-14 | Tularik Inc. | Fxr modulators |
JP2004515494A (en) | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | Therapeutic agent |
WO2002058690A2 (en) | 2001-01-26 | 2002-08-01 | Chugai Seiyaku Kabushiki Kaisha | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
US6649606B1 (en) | 2001-11-09 | 2003-11-18 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
WO2003082198A2 (en) | 2002-03-27 | 2003-10-09 | Smithkline Beecham Corporation | Methods of treatment with lxr modulators |
JP2006502970A (en) | 2002-04-29 | 2006-01-26 | ノバルティス アクチエンゲゼルシャフト | Crystal structure of the ligand binding domain of retinoic acid-related orphan receptor alpha (ROR-alpha) |
EP1646394A2 (en) | 2003-07-22 | 2006-04-19 | Glaxo Group Limited | Methods of treatment with lxr agonists |
WO2005013946A2 (en) | 2003-07-28 | 2005-02-17 | Glaxo Group Limited | Methods of treatment inflammatory bowel with lxr agonists |
WO2005055998A1 (en) | 2003-12-04 | 2005-06-23 | Smithkline Beecham Corporation | Methods of treatment with lxr agonists |
WO2006091862A2 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Cytokine inhibitors and their use in therapy |
WO2007058990A2 (en) | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
WO2007055374A1 (en) | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | Therapeutic agent for osteoporosis |
UY30118A1 (en) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | AMIS TRISUSTITUDE COMPUTER |
AR059826A1 (en) | 2006-03-13 | 2008-04-30 | Univ California | UREA INHIBITORS CONFORMATIONALLY RESTRICTED OF SOLUBLE HYDROLASSE EPOXIDE |
EP2035005A4 (en) | 2006-06-09 | 2011-07-06 | Kemia Inc | Therapy using cytokine inhibitors |
TW200812962A (en) | 2006-07-12 | 2008-03-16 | Astrazeneca Ab | New compounds I/418 |
WO2008008020A1 (en) * | 2006-07-12 | 2008-01-17 | Astrazeneca Ab | 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents |
TW200819435A (en) | 2006-09-15 | 2008-05-01 | Celgene Corp | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same |
JP4834699B2 (en) | 2007-07-30 | 2011-12-14 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
JP4846769B2 (en) | 2007-07-30 | 2011-12-28 | 田辺三菱製薬株式会社 | Pharmaceutical composition |
WO2011115892A1 (en) * | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulators of the retinoic acid receptor-related orphan receptors |
WO2012027965A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
WO2012028100A1 (en) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Novel compounds |
WO2012100732A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Retinoid-related orphan receptor gamma modulators, composition containing them and uses thereof |
WO2012100734A1 (en) | 2011-01-24 | 2012-08-02 | Glaxo Group Limited | Compounds useful as retinoid-related orphan receptor gamma modulators |
EP2487159A1 (en) | 2011-02-11 | 2012-08-15 | MSD Oss B.V. | RorgammaT inhibitors |
WO2012158784A2 (en) | 2011-05-16 | 2012-11-22 | Theodore Mark Kamenecka | Modulators of the nuclear hormone receptor ror |
WO2013029338A1 (en) | 2011-09-01 | 2013-03-07 | Glaxo Group Limited | Novel compounds |
WO2013100027A1 (en) | 2011-12-28 | 2013-07-04 | 武田薬品工業株式会社 | Heterocyclic compound |
US9365512B2 (en) | 2012-02-13 | 2016-06-14 | AbbVie Deutschland GmbH & Co. KG | Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
US9321750B2 (en) | 2012-04-20 | 2016-04-26 | Innov17 Llc | ROR modulators and their uses |
EP2844259A4 (en) | 2012-04-30 | 2015-11-11 | Anderson Gaweco | Ror modulators and their uses |
US9447069B2 (en) | 2012-04-30 | 2016-09-20 | Innov17 Llc | ROR modulators and their uses |
KR101936851B1 (en) * | 2012-07-16 | 2019-01-11 | 한국과학기술연구원 | Pyrazolopyridine or indazole derivatives as protein kinase inhibitors |
WO2013171729A2 (en) | 2013-01-08 | 2013-11-21 | Glenmark Pharmaceuticals S.A. | Aryl and heteroaryl amide compounds as rorgamat modulator |
WO2014125426A1 (en) | 2013-02-15 | 2014-08-21 | Aurigene Discovery Technologies Limited | Trisubstituted heterocyclic derivatives as ror gamma modulators |
US10005720B2 (en) | 2013-04-05 | 2018-06-26 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
EP2991994B1 (en) | 2013-05-01 | 2018-08-15 | Vitae Pharmaceuticals, Inc. | Thiazolopyrrolidine inhibitors of ror-gamma |
US10053468B2 (en) | 2013-07-03 | 2018-08-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
JP6411342B2 (en) | 2013-07-03 | 2018-10-24 | 武田薬品工業株式会社 | Amide compounds |
WO2015017335A1 (en) | 2013-07-30 | 2015-02-05 | Boehringer Ingelheim International Gmbh | Azaindole compounds as modulators of rorc |
EP3041821B1 (en) | 2013-09-05 | 2018-05-30 | Boehringer Ingelheim International GmbH | Bicylic compounds as modulators of rorgamma |
ES2722409T3 (en) | 2013-12-05 | 2019-08-09 | Lead Pharma Holding Bv | ROR gamma modulators (RORy) |
WO2015083130A1 (en) | 2013-12-06 | 2015-06-11 | Aurigene Discovery Technologies Limited | Fused pyridine and pyrimidine derivatives as ror gamma modulators |
WO2015101928A1 (en) | 2013-12-31 | 2015-07-09 | Aurigene Discovery Technologies Limited | Fused thiophene and thiazole derivatives as ror gamma modulators |
EP3527569B1 (en) | 2014-02-03 | 2021-08-25 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma for use in treating drye eye |
JPWO2015129853A1 (en) | 2014-02-27 | 2017-03-30 | 東レ株式会社 | Cyclic amine derivatives and their pharmaceutical use |
EP3122721A4 (en) | 2014-03-27 | 2018-01-10 | Piramal Enterprises Limited | Ror-gamma modulators and uses thereof |
PL3131902T3 (en) | 2014-04-14 | 2019-11-29 | Boehringer Ingelheim Int | Compounds as modulators of ror gamma |
JP2017513850A (en) | 2014-04-16 | 2017-06-01 | グレンマーク・ファーマシューティカルズ・エスエー | Aryl and heteroaryl ether compounds which are ROR gamma modulators |
CR20170017A (en) | 2014-07-01 | 2017-05-16 | Takeda Pharmaceuticals Co | HETEROCYCLIC COMPOUND |
MA40552A (en) | 2014-08-04 | 2021-05-19 | Nuevolution As | PYRIMIDINE DERIVATIVES POSSIBLY CONDENSED SUBSTITUTED BY A HETEROCYCLE USEFUL IN THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOIMMUNE DISEASES |
MA40759A (en) | 2014-09-26 | 2017-08-01 | Pfizer | PYRROLOPYRIDINE-SUBSTITUTED BY METHYL AND TRIFLUOROMETHYL RORC2 MODULATORS AND THEIR METHODS OF USE |
PT3207043T (en) | 2014-10-14 | 2019-03-25 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridine inhibitors of ror-gamma |
US10865181B2 (en) | 2014-11-05 | 2020-12-15 | University Of Kansas | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
WO2016176399A1 (en) | 2015-04-28 | 2016-11-03 | Stc.Unm | Compositions and methods for treatment of pulmonary hypertension |
DK3294713T5 (en) | 2015-05-15 | 2021-05-31 | Aurigene Discovery Tech Ltd | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS TUBE-GAMMA MODULATORS |
EP3101009A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
EP3101005A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
EP3101007A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
EP3101006A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
EP3101008A1 (en) | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
WO2017010399A1 (en) | 2015-07-10 | 2017-01-19 | 塩野義製薬株式会社 | COMPOUNDS HAVING RORγt INHIBITORY EFFECTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
EP3331876B1 (en) | 2015-08-05 | 2020-10-07 | Vitae Pharmaceuticals, LLC | Modulators of ror-gamma |
JP6778259B2 (en) | 2015-10-01 | 2020-10-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Pteridine derivative as a modulator of ROR gamma |
CN109071516B (en) | 2015-12-15 | 2021-08-31 | 阿斯利康(瑞典)有限公司 | Novel compounds |
-
2016
- 2016-12-14 CN CN201680072754.5A patent/CN109071516B/en active Active
- 2016-12-14 KR KR1020187019921A patent/KR101947976B1/en active IP Right Grant
- 2016-12-14 JP JP2018530875A patent/JP6448867B2/en active Active
- 2016-12-14 ES ES16820199T patent/ES2927631T3/en active Active
- 2016-12-14 BR BR112018011851-6A patent/BR112018011851A2/en not_active Application Discontinuation
- 2016-12-14 CA CA3007893A patent/CA3007893A1/en active Pending
- 2016-12-14 PE PE2018001126A patent/PE20181319A1/en unknown
- 2016-12-14 TW TW105141323A patent/TWI728017B/en active
- 2016-12-14 EP EP16820199.4A patent/EP3390396B1/en active Active
- 2016-12-14 MX MX2018007296A patent/MX2018007296A/en active IP Right Grant
- 2016-12-14 US US15/378,360 patent/US10011566B2/en active Active
- 2016-12-14 MY MYPI2018702277A patent/MY196276A/en unknown
- 2016-12-14 EA EA201891342A patent/EA034514B1/en not_active IP Right Cessation
- 2016-12-14 WO PCT/EP2016/080885 patent/WO2017102784A1/en active Application Filing
- 2016-12-14 TN TNP/2018/000188A patent/TN2018000188A1/en unknown
- 2016-12-14 SG SG11201804587QA patent/SG11201804587QA/en unknown
- 2016-12-14 CR CR20180328A patent/CR20180328A/en unknown
- 2016-12-14 AU AU2016374294A patent/AU2016374294B2/en active Active
- 2016-12-15 AR ARP160103860A patent/AR107054A1/en unknown
-
2018
- 2018-06-04 US US15/997,310 patent/US10526286B2/en active Active
- 2018-06-05 IL IL259818A patent/IL259818B/en active IP Right Grant
- 2018-06-08 PH PH12018501237A patent/PH12018501237A1/en unknown
- 2018-06-13 NI NI201800071A patent/NI201800071A/en unknown
- 2018-06-13 CO CONC2018/0005983A patent/CO2018005983A2/en unknown
- 2018-06-13 CL CL2018001573A patent/CL2018001573A1/en unknown
- 2018-06-14 DO DO2018000148A patent/DOP2018000148A/en unknown
- 2018-06-15 SV SV2018005713A patent/SV2018005713A/en unknown
- 2018-07-11 ZA ZA2018/04618A patent/ZA201804618B/en unknown
-
2019
- 2019-11-25 US US16/693,866 patent/US10988445B2/en active Active
-
2021
- 2021-03-26 US US17/213,326 patent/US11453644B1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201510019D0 (en) | Compounds | |
ZA201804618B (en) | Isoindole compounds | |
GB201514754D0 (en) | Compounds | |
GB201514751D0 (en) | Compounds | |
GB201508747D0 (en) | Compounds | |
PL3362444T3 (en) | Compounds | |
GB201520500D0 (en) | Compounds | |
GB201520499D0 (en) | Compounds | |
GB201508864D0 (en) | Compounds | |
IL253813A0 (en) | Diaza-benzofluoranthrene compounds | |
GB201510493D0 (en) | Compounds | |
LT3331885T (en) | Compounds | |
GB201521682D0 (en) | Compounds | |
GB201520419D0 (en) | Compounds | |
GB201508857D0 (en) | Compounds | |
GB201503926D0 (en) | Compounds | |
GB201501115D0 (en) | Compounds | |
GB201522246D0 (en) | Compounds | |
GB201521912D0 (en) | Compounds | |
GB201521440D0 (en) | Compounds | |
GB201521086D0 (en) | Compounds | |
GB201519969D0 (en) | Compounds | |
GB201519965D0 (en) | Compounds | |
GB201519549D0 (en) | Compounds | |
GB201519212D0 (en) | Compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted |